StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)

Stock analysts at StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a note issued to investors on Friday. The firm set a “hold” rating on the stock.

TherapeuticsMD Stock Performance

Shares of TherapeuticsMD stock opened at $1.40 on Friday. The company’s 50 day moving average price is $1.61 and its 200-day moving average price is $1.78. TherapeuticsMD has a 52-week low of $1.36 and a 52-week high of $3.07.

Institutional Inflows and Outflows

An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP increased its stake in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 636,622 shares of the company’s stock after buying an additional 101,282 shares during the period. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent SEC filing. 30.74% of the stock is owned by institutional investors and hedge funds.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.